Frequency of Contralateral Prophylactic Mastectomy in Breast Cancer Patients with a Negative BRCA1 and BRCA2 Rapid Genetic Test Result
Background There is an increasing desire for contralateral prophylactic mastectomy (CPM) among patients with unilateral breast cancer. It is unknown if risk assessment and genetic testing at the time of diagnosis will aid women in their surgical choice. We report on the uptake and predictors of CPM...
Gespeichert in:
| Veröffentlicht in: | Annals of surgical oncology 2021-09, Vol.28 (9), p.4967-4973 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 4973 |
|---|---|
| container_issue | 9 |
| container_start_page | 4967 |
| container_title | Annals of surgical oncology |
| container_volume | 28 |
| creator | Metcalfe, Kelly A. Eisen, Andrea Poll, Aletta Candib, Alexandra McCready, David Cil, Tulin Wright, Frances Demsky, Rochelle Mancuso, Talia Sun, Ping Narod, Steven A |
| description | Background
There is an increasing desire for contralateral prophylactic mastectomy (CPM) among patients with unilateral breast cancer. It is unknown if risk assessment and genetic testing at the time of diagnosis will aid women in their surgical choice. We report on the uptake and predictors of CPM in women receiving a negative genetic test result for
BRCA1
and
BRCA2
mutations before surgery.
Methods
Women diagnosed with breast cancer between June 2013 and May 2018 were recruited from four academic health sciences centers in Toronto, Canada. Genetic counseling (risk assessment) and genetic testing was performed prior to surgery. Women were asked about their surgical preference before surgery. At 1 year post-surgery we asked what surgery was completed. This study reports on women who received a negative
BRCA1
/
BRCA2
result.
Results
A total of 766 women with a mean age of 46 years (range 21–82) were included in the analysis. Before genetic counseling and testing, 37% of the women were undecided or leaning towards CPM; however, after receiving a negative
BRCA
test, 15% of the women opted for CPM. Thirty percent of women whose mother died of breast cancer elected for CPM, compared with 15% of women whose mother did not die of breast cancer (
p
= 0.03).
Conclusions
Women receiving a risk assessment and negative
BRCA1
/
BRCA
2 genetic test result before surgery use this information to guide their surgical decision. Uptake of CPM for women who were planning on CPM before genetic testing decreases after receiving a negative
BRCA1/BRCA2
genetic test result. |
| doi_str_mv | 10.1245/s10434-021-09855-6 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2505366277</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2559154449</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-cba47ee65d86c774dc2cb06cc64093be834519342759256465b16503444db9c3</originalsourceid><addsrcrecordid>eNp9kc1O3DAUhS1EBZT2BVhUlth0k9b_TpYQFVqJtmg0e8tx7kBQxhlsh2peoM_dCwOt1AUb-_r6O8c_h5ATzj5xofTnzJmSqmKCV6ypta7MHjniGlvK1Hwfa2bqqhFGH5K3Od8xxq1k-oAcSmkNR90R-X2R4H6GGLZ0WtF2iiX50RfAkV6naXO7HX0oQ6DffS4QyrTe0iHS8wS4pq2PARK99mWAWDL9NZRb6ukPuMHOA9DzRXvGqY_9UyXowm-Gnl5ChEfLJaDFAvI8lnfkzcqPGd4_z8dkefFl2X6trn5efmvPrqogrS5V6LyyAEb3tQnWqj6I0DETglGskR3UUmneSCWsboQ2yuiOG82kUqrvmiCPyced7SZN-Opc3HrIAcbRR5jm7IRmWhojrEX09D_0bppTxMshpRuu0bNBSuyokKacE6zcJg1rn7aOM_cYktuF5PCz3VNIzqDow7P13K2h_yt5SQUBuQMybsUbSP_OfsX2D_wAmzE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2559154449</pqid></control><display><type>article</type><title>Frequency of Contralateral Prophylactic Mastectomy in Breast Cancer Patients with a Negative BRCA1 and BRCA2 Rapid Genetic Test Result</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Metcalfe, Kelly A. ; Eisen, Andrea ; Poll, Aletta ; Candib, Alexandra ; McCready, David ; Cil, Tulin ; Wright, Frances ; Demsky, Rochelle ; Mancuso, Talia ; Sun, Ping ; Narod, Steven A</creator><creatorcontrib>Metcalfe, Kelly A. ; Eisen, Andrea ; Poll, Aletta ; Candib, Alexandra ; McCready, David ; Cil, Tulin ; Wright, Frances ; Demsky, Rochelle ; Mancuso, Talia ; Sun, Ping ; Narod, Steven A</creatorcontrib><description>Background
There is an increasing desire for contralateral prophylactic mastectomy (CPM) among patients with unilateral breast cancer. It is unknown if risk assessment and genetic testing at the time of diagnosis will aid women in their surgical choice. We report on the uptake and predictors of CPM in women receiving a negative genetic test result for
BRCA1
and
BRCA2
mutations before surgery.
Methods
Women diagnosed with breast cancer between June 2013 and May 2018 were recruited from four academic health sciences centers in Toronto, Canada. Genetic counseling (risk assessment) and genetic testing was performed prior to surgery. Women were asked about their surgical preference before surgery. At 1 year post-surgery we asked what surgery was completed. This study reports on women who received a negative
BRCA1
/
BRCA2
result.
Results
A total of 766 women with a mean age of 46 years (range 21–82) were included in the analysis. Before genetic counseling and testing, 37% of the women were undecided or leaning towards CPM; however, after receiving a negative
BRCA
test, 15% of the women opted for CPM. Thirty percent of women whose mother died of breast cancer elected for CPM, compared with 15% of women whose mother did not die of breast cancer (
p
= 0.03).
Conclusions
Women receiving a risk assessment and negative
BRCA1
/
BRCA
2 genetic test result before surgery use this information to guide their surgical decision. Uptake of CPM for women who were planning on CPM before genetic testing decreases after receiving a negative
BRCA1/BRCA2
genetic test result.</description><identifier>ISSN: 1068-9265</identifier><identifier>EISSN: 1534-4681</identifier><identifier>DOI: 10.1245/s10434-021-09855-6</identifier><identifier>PMID: 33761021</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Adult ; Aged ; Aged, 80 and over ; BRCA1 protein ; BRCA1 Protein - genetics ; BRCA2 protein ; BRCA2 Protein - genetics ; Breast cancer ; Breast Neoplasms - genetics ; Breast Neoplasms - prevention & control ; Breast Neoplasms - surgery ; Breast Oncology ; Female ; Genes, BRCA1 ; Genes, BRCA2 ; Genetic analysis ; Genetic counseling ; Genetic screening ; Genetic Testing ; Humans ; Mastectomy ; Medicine ; Medicine & Public Health ; Middle Aged ; Mutation ; Oncology ; Patients ; Prophylactic Mastectomy ; Risk assessment ; Surgery ; Surgical Oncology ; Young Adult</subject><ispartof>Annals of surgical oncology, 2021-09, Vol.28 (9), p.4967-4973</ispartof><rights>Society of Surgical Oncology 2021</rights><rights>2021. Society of Surgical Oncology.</rights><rights>Society of Surgical Oncology 2021.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-cba47ee65d86c774dc2cb06cc64093be834519342759256465b16503444db9c3</citedby><cites>FETCH-LOGICAL-c375t-cba47ee65d86c774dc2cb06cc64093be834519342759256465b16503444db9c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1245/s10434-021-09855-6$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1245/s10434-021-09855-6$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27903,27904,41467,42536,51298</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33761021$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Metcalfe, Kelly A.</creatorcontrib><creatorcontrib>Eisen, Andrea</creatorcontrib><creatorcontrib>Poll, Aletta</creatorcontrib><creatorcontrib>Candib, Alexandra</creatorcontrib><creatorcontrib>McCready, David</creatorcontrib><creatorcontrib>Cil, Tulin</creatorcontrib><creatorcontrib>Wright, Frances</creatorcontrib><creatorcontrib>Demsky, Rochelle</creatorcontrib><creatorcontrib>Mancuso, Talia</creatorcontrib><creatorcontrib>Sun, Ping</creatorcontrib><creatorcontrib>Narod, Steven A</creatorcontrib><title>Frequency of Contralateral Prophylactic Mastectomy in Breast Cancer Patients with a Negative BRCA1 and BRCA2 Rapid Genetic Test Result</title><title>Annals of surgical oncology</title><addtitle>Ann Surg Oncol</addtitle><addtitle>Ann Surg Oncol</addtitle><description>Background
There is an increasing desire for contralateral prophylactic mastectomy (CPM) among patients with unilateral breast cancer. It is unknown if risk assessment and genetic testing at the time of diagnosis will aid women in their surgical choice. We report on the uptake and predictors of CPM in women receiving a negative genetic test result for
BRCA1
and
BRCA2
mutations before surgery.
Methods
Women diagnosed with breast cancer between June 2013 and May 2018 were recruited from four academic health sciences centers in Toronto, Canada. Genetic counseling (risk assessment) and genetic testing was performed prior to surgery. Women were asked about their surgical preference before surgery. At 1 year post-surgery we asked what surgery was completed. This study reports on women who received a negative
BRCA1
/
BRCA2
result.
Results
A total of 766 women with a mean age of 46 years (range 21–82) were included in the analysis. Before genetic counseling and testing, 37% of the women were undecided or leaning towards CPM; however, after receiving a negative
BRCA
test, 15% of the women opted for CPM. Thirty percent of women whose mother died of breast cancer elected for CPM, compared with 15% of women whose mother did not die of breast cancer (
p
= 0.03).
Conclusions
Women receiving a risk assessment and negative
BRCA1
/
BRCA
2 genetic test result before surgery use this information to guide their surgical decision. Uptake of CPM for women who were planning on CPM before genetic testing decreases after receiving a negative
BRCA1/BRCA2
genetic test result.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>BRCA1 protein</subject><subject>BRCA1 Protein - genetics</subject><subject>BRCA2 protein</subject><subject>BRCA2 Protein - genetics</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - genetics</subject><subject>Breast Neoplasms - prevention & control</subject><subject>Breast Neoplasms - surgery</subject><subject>Breast Oncology</subject><subject>Female</subject><subject>Genes, BRCA1</subject><subject>Genes, BRCA2</subject><subject>Genetic analysis</subject><subject>Genetic counseling</subject><subject>Genetic screening</subject><subject>Genetic Testing</subject><subject>Humans</subject><subject>Mastectomy</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Mutation</subject><subject>Oncology</subject><subject>Patients</subject><subject>Prophylactic Mastectomy</subject><subject>Risk assessment</subject><subject>Surgery</subject><subject>Surgical Oncology</subject><subject>Young Adult</subject><issn>1068-9265</issn><issn>1534-4681</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kc1O3DAUhS1EBZT2BVhUlth0k9b_TpYQFVqJtmg0e8tx7kBQxhlsh2peoM_dCwOt1AUb-_r6O8c_h5ATzj5xofTnzJmSqmKCV6ypta7MHjniGlvK1Hwfa2bqqhFGH5K3Od8xxq1k-oAcSmkNR90R-X2R4H6GGLZ0WtF2iiX50RfAkV6naXO7HX0oQ6DffS4QyrTe0iHS8wS4pq2PARK99mWAWDL9NZRb6ukPuMHOA9DzRXvGqY_9UyXowm-Gnl5ChEfLJaDFAvI8lnfkzcqPGd4_z8dkefFl2X6trn5efmvPrqogrS5V6LyyAEb3tQnWqj6I0DETglGskR3UUmneSCWsboQ2yuiOG82kUqrvmiCPyced7SZN-Opc3HrIAcbRR5jm7IRmWhojrEX09D_0bppTxMshpRuu0bNBSuyokKacE6zcJg1rn7aOM_cYktuF5PCz3VNIzqDow7P13K2h_yt5SQUBuQMybsUbSP_OfsX2D_wAmzE</recordid><startdate>20210901</startdate><enddate>20210901</enddate><creator>Metcalfe, Kelly A.</creator><creator>Eisen, Andrea</creator><creator>Poll, Aletta</creator><creator>Candib, Alexandra</creator><creator>McCready, David</creator><creator>Cil, Tulin</creator><creator>Wright, Frances</creator><creator>Demsky, Rochelle</creator><creator>Mancuso, Talia</creator><creator>Sun, Ping</creator><creator>Narod, Steven A</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20210901</creationdate><title>Frequency of Contralateral Prophylactic Mastectomy in Breast Cancer Patients with a Negative BRCA1 and BRCA2 Rapid Genetic Test Result</title><author>Metcalfe, Kelly A. ; Eisen, Andrea ; Poll, Aletta ; Candib, Alexandra ; McCready, David ; Cil, Tulin ; Wright, Frances ; Demsky, Rochelle ; Mancuso, Talia ; Sun, Ping ; Narod, Steven A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-cba47ee65d86c774dc2cb06cc64093be834519342759256465b16503444db9c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>BRCA1 protein</topic><topic>BRCA1 Protein - genetics</topic><topic>BRCA2 protein</topic><topic>BRCA2 Protein - genetics</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - genetics</topic><topic>Breast Neoplasms - prevention & control</topic><topic>Breast Neoplasms - surgery</topic><topic>Breast Oncology</topic><topic>Female</topic><topic>Genes, BRCA1</topic><topic>Genes, BRCA2</topic><topic>Genetic analysis</topic><topic>Genetic counseling</topic><topic>Genetic screening</topic><topic>Genetic Testing</topic><topic>Humans</topic><topic>Mastectomy</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Mutation</topic><topic>Oncology</topic><topic>Patients</topic><topic>Prophylactic Mastectomy</topic><topic>Risk assessment</topic><topic>Surgery</topic><topic>Surgical Oncology</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Metcalfe, Kelly A.</creatorcontrib><creatorcontrib>Eisen, Andrea</creatorcontrib><creatorcontrib>Poll, Aletta</creatorcontrib><creatorcontrib>Candib, Alexandra</creatorcontrib><creatorcontrib>McCready, David</creatorcontrib><creatorcontrib>Cil, Tulin</creatorcontrib><creatorcontrib>Wright, Frances</creatorcontrib><creatorcontrib>Demsky, Rochelle</creatorcontrib><creatorcontrib>Mancuso, Talia</creatorcontrib><creatorcontrib>Sun, Ping</creatorcontrib><creatorcontrib>Narod, Steven A</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of surgical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Metcalfe, Kelly A.</au><au>Eisen, Andrea</au><au>Poll, Aletta</au><au>Candib, Alexandra</au><au>McCready, David</au><au>Cil, Tulin</au><au>Wright, Frances</au><au>Demsky, Rochelle</au><au>Mancuso, Talia</au><au>Sun, Ping</au><au>Narod, Steven A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Frequency of Contralateral Prophylactic Mastectomy in Breast Cancer Patients with a Negative BRCA1 and BRCA2 Rapid Genetic Test Result</atitle><jtitle>Annals of surgical oncology</jtitle><stitle>Ann Surg Oncol</stitle><addtitle>Ann Surg Oncol</addtitle><date>2021-09-01</date><risdate>2021</risdate><volume>28</volume><issue>9</issue><spage>4967</spage><epage>4973</epage><pages>4967-4973</pages><issn>1068-9265</issn><eissn>1534-4681</eissn><abstract>Background
There is an increasing desire for contralateral prophylactic mastectomy (CPM) among patients with unilateral breast cancer. It is unknown if risk assessment and genetic testing at the time of diagnosis will aid women in their surgical choice. We report on the uptake and predictors of CPM in women receiving a negative genetic test result for
BRCA1
and
BRCA2
mutations before surgery.
Methods
Women diagnosed with breast cancer between June 2013 and May 2018 were recruited from four academic health sciences centers in Toronto, Canada. Genetic counseling (risk assessment) and genetic testing was performed prior to surgery. Women were asked about their surgical preference before surgery. At 1 year post-surgery we asked what surgery was completed. This study reports on women who received a negative
BRCA1
/
BRCA2
result.
Results
A total of 766 women with a mean age of 46 years (range 21–82) were included in the analysis. Before genetic counseling and testing, 37% of the women were undecided or leaning towards CPM; however, after receiving a negative
BRCA
test, 15% of the women opted for CPM. Thirty percent of women whose mother died of breast cancer elected for CPM, compared with 15% of women whose mother did not die of breast cancer (
p
= 0.03).
Conclusions
Women receiving a risk assessment and negative
BRCA1
/
BRCA
2 genetic test result before surgery use this information to guide their surgical decision. Uptake of CPM for women who were planning on CPM before genetic testing decreases after receiving a negative
BRCA1/BRCA2
genetic test result.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>33761021</pmid><doi>10.1245/s10434-021-09855-6</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1068-9265 |
| ispartof | Annals of surgical oncology, 2021-09, Vol.28 (9), p.4967-4973 |
| issn | 1068-9265 1534-4681 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2505366277 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Adult Aged Aged, 80 and over BRCA1 protein BRCA1 Protein - genetics BRCA2 protein BRCA2 Protein - genetics Breast cancer Breast Neoplasms - genetics Breast Neoplasms - prevention & control Breast Neoplasms - surgery Breast Oncology Female Genes, BRCA1 Genes, BRCA2 Genetic analysis Genetic counseling Genetic screening Genetic Testing Humans Mastectomy Medicine Medicine & Public Health Middle Aged Mutation Oncology Patients Prophylactic Mastectomy Risk assessment Surgery Surgical Oncology Young Adult |
| title | Frequency of Contralateral Prophylactic Mastectomy in Breast Cancer Patients with a Negative BRCA1 and BRCA2 Rapid Genetic Test Result |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T02%3A11%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Frequency%20of%20Contralateral%20Prophylactic%20Mastectomy%20in%20Breast%20Cancer%20Patients%20with%20a%20Negative%20BRCA1%20and%20BRCA2%20Rapid%20Genetic%20Test%20Result&rft.jtitle=Annals%20of%20surgical%20oncology&rft.au=Metcalfe,%20Kelly%20A.&rft.date=2021-09-01&rft.volume=28&rft.issue=9&rft.spage=4967&rft.epage=4973&rft.pages=4967-4973&rft.issn=1068-9265&rft.eissn=1534-4681&rft_id=info:doi/10.1245/s10434-021-09855-6&rft_dat=%3Cproquest_cross%3E2559154449%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2559154449&rft_id=info:pmid/33761021&rfr_iscdi=true |